NCT07714525 Triamcinolone Acetonide Nasal Polyps Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07714525 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 21 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07714525 is a hot trial to watch
Nasal Polyps is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07714525 is notable because it evaluates Triamcinolone Acetonide in a Phase 2 design sponsored by Deraya University. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07714525 |
| Official title | Triamcinolone Nanocapsules After Endoscopic Nasal Surgery |
| Phase / status | Phase 2 / Recruiting |
| Intervention | Triamcinolone Acetonide |
| Sponsor | Deraya University |
| Geography | Egypt |
| Enrollment | 50 |
| Primary endpoint | Change in Lund-Kennedy Endoscopic Score |
| Endpoint time frame | Baseline, postoperative week 2, postoperative week 4, and postoperative month 3 |
| Primary completion / readout proxy | 2027-05-01 |
Protocol design and endpoint interpretation
This randomised, single-masked, parallel-group clinical trial will evaluate the efficacy and safety of a topical triamcinolone acetonide-loaded polymeric nanocapsule formulation for postoperative care following endoscopic nasal surgery. Participants will receive either the investigational triamcinolone acetonide-loaded nanocapsule formulation or standard normal saline nasal irrigation. Postoperative nasal healing, inflammation, patient-reported sinonasal symptoms, postoperative complications, and corticosteroid-related adverse effects will be compared between the two groups.
Allocation is Randomized, masking is Single, and the intervention model is Parallel Assignment. Planned enrollment of 50 participants across Egypt shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Change in Lund-Kennedy Endoscopic Score (Baseline, postoperative week 2, postoperative week 4, and postoperative month 3) — Postoperative nasal mucosal healing and inflammation will be assessed using the Lund-Kennedy endoscopic scoring system.
- Change in 22-Item Sinonasal Outcome Test Score (Baseline, postoperative week 2, postoperative week 4, and postoperative month 3) — Participant-reported sinonasal symptoms and health-related quality of life will be assessed using the 22-Item Sinonasal Outcome Test, SNOT-22.
Readout outlook and evidence gap
The current protocol points to 2027-05-01 as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Trial-sourced asset: Triamcinolone Acetonide. The Drug & Asset MCP enrichment step is designed to add normalized targets, modality and global development status when an exact asset match is available.
Trial-sourced sponsor: Deraya University. Company & Deal Intelligence MCP is the companion workflow for resolving organization identity, corporate profile and partnering context.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07714525 provides a focused lens on Nasal Polyps development. Its value will be determined by whether Triamcinolone Acetonide can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
